Monica Schwarcz, MD
Endocrinology, Diabetes & Metabolism · Valhalla, NYNPI 1184818049
Payments from drug & device makers
Across 188 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$623
- AstraZeneca$553
- Amgen$496
- AbbVie$384
- Lilly USA, LLC$341
- Abbott$249
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,153100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 30 | $623 |
| AstraZeneca | 23 | $553 |
| Amgen(2 entities) | 13 | $496 |
| AbbVie | 20 | $384 |
| Lilly USA, LLC | 28 | $341 |
| Abbott | 10 | $249 |
| Kvk-tech, Inc. | 1 | $224 |
| Mannkind Corporation | 10 | $183 |
| Bayer | 7 | $162 |
| Amneal Pharmaceuticals LLC | 7 | $157 |
| Currax Pharmaceuticals LLC | 7 | $122 |
| Corcept Therapeutics | 3 | $89 |
| Novartis | 4 | $70 |
| Pfizer | 2 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Radius Health, Inc. | 3 | $57 |
| Intra-sana Laboratories | 2 | $54 |
| Insulet Corporation | 1 | $31 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| IBSA Pharma Inc. | 1 | $19 |
| EUSA Pharma (US) LLC | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Evofem Biosciences, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Merck | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| GRT US Holding, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,153 in reported general payments places this provider in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 219 | $381,564 |
| MounjaroTirzepatide | 183 | $242,109 |
| FarxigaDapagliflozin Propanediol | 55 | $63,170 |
| JardianceEmpagliflozin | 46 | $62,532 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 17 | $30,690 |
| Teriparatide | 13 | $26,541 |
| JanuviaSitagliptin Phosphate | 34 | $20,656 |
| SynthroidLevothyroxine Sodium | 155 | $11,136 |
| TradjentaLinagliptin | 11 | $8,612 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $8,582 |
| Humalog Kwikpen U-100Insulin Lispro | 19 | $6,555 |
| HumalogInsulin Lispro | 12 | $4,369 |
| Levothyroxine Sodium | 343 | $3,916 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 42 | $3,849 |
| Novolog FlexpenInsulin Aspart | 16 | $3,459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $623 | $381,564219 claims |
| Lilly USA, LLCMounjaro, Humalog | $341 | $246,478195 claims |
| Boehringer IngelheimJardiance, Tradjenta | $22 | $71,14457 claims |
| AstraZenecaFarxiga | $553 | $63,17055 claims |
| MerckJanuvia | $16 | $20,65634 claims |
| AbbVieSynthroid, Armour Thyroid | $384 | $12,138166 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $157 | $3,916343 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Valhalla
- Michael GoldbergValhalla$255K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.